twit 25   linkedin 25

16 / Jan 15

GeNeuro announces the registration of its document de base as part of its planned IPO on Euronext's regulated market in Paris

GeNeuro, a biopharmaceutical company developing new treatments for autoimmune diseases including multiple sclerosis (MS), announces today the registration of its document de base with the French Autorité des Marchés Financiers (AMF) under number I.16-002 on January 14, 2016 as part of its planned IPO on Euronext's regulated market in Paris.
The registration of the document de base is the first step in GeNeuro's planned IPO on Euronext's regulated market in Paris, which is contingent on market conditions and regulatory requirements including the AMF's approval of a prospectus to be prepared as part of the transaction.
GeNeuro is developing a new approach to the treatment of multiple sclerosis (MS) by seeking to block upstream inflammatory and neurodegenerative mechanisms, rather than interfering with the body's immune response as most current treatments do.

About NewCap

As a specialist in investor relations and strategic communication advice, NewCap advises and supports its clients regarding their sectoral, scientific, institutional and financial communication strategies.

CONTACT

contact 01Address :
21, place de la Madeleine - 75008 Paris

contact 02Phone :
+33 (0)1 44 71 94 94

contact 03Email :
infos(at)newcap.fr